Oncology
Pipeline

Gene

About our Oncology efforts

We have a clear aspiration – to transform the lives of people with cancer by delivering meaningful advances, with the ultimate goal of curing a range of cancers. Our generational commitment to driving scientific innovation is reflected by our robust pipeline of cancer cell-directed and immuno-oncology investigational therapies, as well as the smart combination of these approaches. We are taking a diligent and broad approach, creating a collaborative research network to tap into a diversity of minds, which is vital in addressing some of the most challenging, but potentially most impactful, areas of cancer research. Simply put, for Boehringer Ingelheim, cancer care is personal, today and for generations.

Read more about Zongertinib (BI 1810631): HER2 Tyrosine Kinase Inhibitor (TKI) | NSCLC

Oncology

Non-small cell lung cancer

HER2 TKI

Zongertinib (BI 1810631)

Read more about BI 764532: DLL3/CD3 T-cell engager

Oncology

Small-cell lung cancer

DLL3/CD3 T-cell engager

Obrixtamig (BI 764532)

Read more about BI 764532: DLL3/CD3 T-cell engager | ep-NEC

Oncology

Extra-pulmonary neuroendocrine carcinoma

DLL3/CD3 T-cell engager

Obrixtamig (BI 764532)

Read more about Brigimadlin (BI 907828): MDM2-p53 antagonist | NSCLC

Oncology

Non-small-cell lung cancer

MDM2-p53 antagonist

Brigimadlin (BI 907828)

Read more about B7-H6/CD3 T-Cell Engager

Oncology

B7-H6/CD3 T-cell engager

Read more about CD137/FAP agonist

Oncology

CD137/FAP agonist

Read more about DLL3/CD3 T-cell engager

Oncology

DLL3/CD3 T-cell engager

Obrixtamig

Read more about Ezabenlimab, PD-1 antibody

Oncology

PD-1 antibody

Ezabenlimab

Read more about HER2 TKI, Zongertinib

Oncology

HER2 TKI

Zongertinib

Read more about KISIMA® Cancer Vaccine

Oncology

KISIMA® cancer vaccine

Read more about KRAS multi-inhibitor

Oncology

KRAS multi-inhibitor

Read more about Modified yersinia

Oncology

Modified yersinia

Read more about Second generation STING agonist

Oncology

STING agonist (2nd generation)

Read more about SIRPα antagonist

Oncology

SIRPa antagonist

Read more about VSV-GP

Oncology

VSV-GP